These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15912428)

  • 1. The utility of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in the investigation of patients with disseminated carcinoma of unknown primary origin.
    Scott CL; Kudaba I; Stewart JM; Hicks RJ; Rischin D
    Mol Imaging Biol; 2005; 7(3):236-43. PubMed ID: 15912428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
    Wu ZJ; Zhang YX; Wei H; Jia Q
    Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary.
    Han A; Xue J; Hu M; Zheng J; Wang X
    Cancer Epidemiol; 2012 Oct; 36(5):470-5. PubMed ID: 22504050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDG PET and PET/CT for the detection of the primary tumour in patients with cervical non-squamous cell carcinoma metastasis of an unknown primary.
    Paul SA; Stoeckli SJ; von Schulthess GK; Goerres GW
    Eur Arch Otorhinolaryngol; 2007 Feb; 264(2):189-95. PubMed ID: 17177026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Occult primary tumors of the head and neck: lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose.
    Greven KM; Keyes JW; Williams DW; McGuirt WF; Joyce WT
    Cancer; 1999 Jul; 86(1):114-8. PubMed ID: 10391570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site.
    Pelosi E; Pennone M; Deandreis D; Douroukas A; Mancini M; Bisi G
    Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):15-22. PubMed ID: 16557200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG PET in patients with cancer of an unknown primary.
    Kolesnikov-Gauthier H; Levy E; Merlet P; Kirova J; Syrota A; Carpentier P; Meignan M; Piedbois P
    Nucl Med Commun; 2005 Dec; 26(12):1059-66. PubMed ID: 16264351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact on Patient Management of [18F]-Fluorodeoxyglucose-Positron Emission Tomography (PET) Used for Cancer Diagnosis: Analysis of Data From the National Oncologic PET Registry.
    Subramaniam RM; Shields AF; Sachedina A; Hanna L; Duan F; Siegel BA; Hillner BE
    Oncologist; 2016 Sep; 21(9):1079-84. PubMed ID: 27401896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities.
    Regelink G; Brouwer J; de Bree R; Pruim J; van der Laan BF; Vaalburg W; Hoekstra OS; Comans EF; Vissink A; Leemans CR; Roodenburg JL
    Eur J Nucl Med Mol Imaging; 2002 Aug; 29(8):1024-30. PubMed ID: 12173016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical value of whole-body F-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with carcinoma of unknown primary.
    Wang G; Wu Y; Zhang W; Li J; Wu P; Xie C
    J Med Imaging Radiat Oncol; 2013 Feb; 57(1):65-71. PubMed ID: 23374557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors.
    Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2009 Mar; 45(3):218-24. PubMed ID: 18804404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2[F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation.
    Jungehülsing M; Scheidhauer K; Damm M; Pietrzyk U; Eckel H; Schicha H; Stennert E
    Otolaryngol Head Neck Surg; 2000 Sep; 123(3):294-301. PubMed ID: 10964310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of survival and evaluation of diagnostic accuracy whole body 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the detection carcinoma of unknown primary origin.
    Tamam MO; Mulazimoglu M; Guveli TK; Tamam C; Eker O; Ozpacaci T
    Eur Rev Med Pharmacol Sci; 2012 Dec; 16(15):2120-30. PubMed ID: 23280029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the management of patients with carcinoma of unknown primary.
    Deonarine P; Han S; Poon FW; de Wet C
    Scott Med J; 2013 Aug; 58(3):154-62. PubMed ID: 23960054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site.
    Sève P; Billotey C; Broussolle C; Dumontet C; Mackey JR
    Cancer; 2007 Jan; 109(2):292-9. PubMed ID: 17167760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in carcinoma of an unknown primary: diagnosis and follow-up.
    Yapar Z; Kibar M; Yapar AF; Paydas S; Reyhan M; Kara O; Buyukdereli G; Aydin M; Kelle AP; Unal I; Disel U; Yavuz S; Sahin B; Erkisi M
    Nucl Med Commun; 2010 Jan; 31(1):59-66. PubMed ID: 19952921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of F-18 fluorodeoxyglucose posıtron emıssıon tomography/computed ın carcınoma of unknown primary.
    Elboga U; Kervancioğlu S; Sahin E; Basibuyuk M; Celen YZ; Aktolun C
    Int J Clin Exp Pathol; 2014; 7(12):8941-6. PubMed ID: 25674269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic accuracy of 18F-2-deoxy-fluoro-D-glucose positron emission tomography for pN1 lymph nodes in patients with lung cancer.
    Nakagawa M; Hara M; Sakurai K; Ozawa Y; Mizuno A; Tamaki T; Nishio M; Shibamoto Y
    Acta Radiol; 2009 Jul; 50(6):638-44. PubMed ID: 19492198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Merkel cell carcinoma: Is there a role for 2-deoxy-2-[f-18]fluoro-D-glucose-positron emission tomography/computed tomography?
    Iagaru A; Quon A; McDougall IR; Gambhir SS
    Mol Imaging Biol; 2006; 8(4):212-7. PubMed ID: 16724293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical applications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in carcinoma of unknown primary.
    Hu M; Zhao W; Zhang PL; Ju GF; Fu Z; Zhang GL; Kong L; Yang YQ; Ma YD; Yu JM
    Chin Med J (Engl); 2011 Apr; 124(7):1010-4. PubMed ID: 21542959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.